BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 17968740)

  • 1. Challenges for blood-brain barrier (BBB) screening.
    Jeffrey P; Summerfield SG
    Xenobiotica; 2007; 37(10-11):1135-51. PubMed ID: 17968740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of the blood-brain barrier in CNS drug discovery.
    Jeffrey P; Summerfield S
    Neurobiol Dis; 2010 Jan; 37(1):33-7. PubMed ID: 19664709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases.
    Löscher W; Potschka H
    Prog Neurobiol; 2005 May; 76(1):22-76. PubMed ID: 16011870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.
    Reichel A
    Chem Biodivers; 2009 Nov; 6(11):2030-49. PubMed ID: 19937839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
    Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional characterization and comparison of the outer blood-retina barrier and the blood-brain barrier.
    Steuer H; Jaworski A; Elger B; Kaussmann M; Keldenich J; Schneider H; Stoll D; Schlosshauer B
    Invest Ophthalmol Vis Sci; 2005 Mar; 46(3):1047-53. PubMed ID: 15728564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Confocal imaging of xenobiotic transport across the blood-brain barrier.
    Miller DS
    J Exp Zool A Comp Exp Biol; 2003 Nov; 300(1):84-90. PubMed ID: 14598390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro models for the blood-brain barrier.
    Garberg P; Ball M; Borg N; Cecchelli R; Fenart L; Hurst RD; Lindmark T; Mabondzo A; Nilsson JE; Raub TJ; Stanimirovic D; Terasaki T; Oberg JO; Osterberg T
    Toxicol In Vitro; 2005 Apr; 19(3):299-334. PubMed ID: 15713540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
    Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology of the blood-brain barrier: animal models and methods.
    Hawkins BT; Egleton RD
    Curr Top Dev Biol; 2008; 80():277-309. PubMed ID: 17950377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in brain penetration evaluation in drug discovery and development.
    Liu X; Chen C; Smith BJ
    J Pharmacol Exp Ther; 2008 May; 325(2):349-56. PubMed ID: 18203948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to optimize brain penetration in drug discovery.
    Liu X; Chen C
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):505-12. PubMed ID: 16022187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biology of the blood-brain barrier: Part I].
    Weiss N; Miller F; Cazaubon S; Couraud PO
    Rev Neurol (Paris); 2009 Nov; 165(11):863-74. PubMed ID: 19427009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-brain barrier in vitro models as tools in drug discovery: assessment of the transport ranking of antihistaminic drugs.
    Neuhaus W; Mandikova J; Pawlowitsch R; Linz B; Bennani-Baiti B; Lauer R; Lachmann B; Noe CR
    Pharmazie; 2012 May; 67(5):432-9. PubMed ID: 22764578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central nervous system drug disposition: the relationship between in situ brain permeability and brain free fraction.
    Summerfield SG; Read K; Begley DJ; Obradovic T; Hidalgo IJ; Coggon S; Lewis AV; Porter RA; Jeffrey P
    J Pharmacol Exp Ther; 2007 Jul; 322(1):205-13. PubMed ID: 17405866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methods to assess drug permeability across the blood-brain barrier.
    Nicolazzo JA; Charman SA; Charman WN
    J Pharm Pharmacol; 2006 Mar; 58(3):281-93. PubMed ID: 16536894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics.
    Ooie T; Terasaki T; Suzuki H; Sugiyama Y
    J Pharmacol Exp Ther; 1997 Oct; 283(1):293-304. PubMed ID: 9336336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Central nervous system distribution kinetics of indinavir in rats.
    Hamidi M
    J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes.
    Nakagawa S; Deli MA; Kawaguchi H; Shimizudani T; Shimono T; Kittel A; Tanaka K; Niwa M
    Neurochem Int; 2009; 54(3-4):253-63. PubMed ID: 19111869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.